Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

MLA

Marc Bosch Schips, et al. “Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS).” Blood, vol. 140, Nov. 2022, pp. 12308–10. EBSCOhost, https://doi.org/10.1182/blood-2022-157434.

APA

Marc Bosch Schips, Julia Montoro, Félix López Cadenas, Alba Mesa, Víctor Navarro Garcés, Ana Pérez, Laura Gallur, Silvia Saumell, Mayda Navarrete, Margarita Ortega, Bárbara Tazón, Antonieta Molero, Olga Salamero, Sandra Novoa Jáuregui, Sofia Laura Muzio, Francesc Bosch, & David Valcárcel. (2022). Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS). Blood, 140, 12308–12310. https://doi.org/10.1182/blood-2022-157434

Chicago

Marc Bosch Schips, Julia Montoro, Félix López Cadenas, Alba Mesa, Víctor Navarro Garcés, Ana Pérez, Laura Gallur, et al. 2022. “Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS).” Blood 140 (November): 12308–10. doi:10.1182/blood-2022-157434.